Chordate Medical Holding AB (publ), ("Chordate," "the Company") announces that the European Patent Office has granted Chordate's patent application EP 20163024.1 from 2020. The patent application pertains to the company's treatment technique Ozilia, especially targeting chronic migraine.
“The purpose of further expanding the patent portfolio is to make it more difficult for a potential competitor to enter our market. The company's intellectual property enables exclusivity in the market, which is a cornerstone of the value that the company is building," says Anders Weilandt, CEO of Chordate Medical.
Chordate Medical now holds 78 patents distributed across 9 patent families, providing protection for various aspects of the company's treatment techniques in 32 countries/regions. The granting and validation of application EP 20163024.1 mean that additional patents have been added to a growing portfolio that the company began building in 2008.